德孚在中国

9 7 3 1 6

论文已发表

提 交 论 文


注册即可获取德孚的最新动态

注 册



IF 收录期刊





更多详情 >>





已发表论文

与两性霉素 B 和氟康唑相比，卡泊芬净在中国的应用

 

Authors Zhang CY, Cheng JY, Jiang Y, Liu JY

Published Date September 2014 Volume 2014:10 Pages 737—741

DOI http://dx.doi.org/10.2147/TCRM.S47146

Received 7 March 2014, Accepted 4 August 2014, Published 10 September 2014

Approved for publication by Dr Deyun Wang

Abstract: Fungal infection has increased in the past 2 decades in China. There are three classes of antifungal drugs, polyenes, azoles, and echinocandins, that are applied frequently in China. Caspofungin, which disrupts the fungal cell wall glucan formation through inhibiting the enzyme 1,3-ß-glucan synthase, is one of the echinocandins. According to the results of clinical practices applied in China, caspofungin has shown to be superior to the other two classes of antifungal drugs, due to its efficacy in treating fungal infection (15% superior to fluconazole); fewer adverse events such as infusion-related reaction, hepatic dysfunction, and vomiting (25%–50% lower incidence rate); rapid resolution of symptoms (about 3 days quicker than amphotericin B); and absence of antagonism in combination with other antifungal drugs. However, caspofungin will remain as a second-line antifungal drug in the near future because of its high price and the policy of health insurance reimbursement in China.
Keywords: fungal infection, caspofungin, efficacy, adverse event





Download Article[PDF]